Syncromune® @syncromune

Developing an in situ cancer therapy that combines partial oncolysis and a multi-target biologic drug optimized to treat metastatic solid tumor cancers syncromune.com FL Joined August 2020

Tweets

36
Followers

68
Following

262
Likes

2

Syncromune® @syncromune

2 weeks ago

In this article titled, “AACR 2024: What Cancer Researchers are Talking About,” @biospace shares some of the hottest topics coming out of the conference, including data from the Phase 1 trial evaluating Syncromune’s SYNC-T therapy in patients with metastatic prostate cancer.…

0 0 2 78 0

Syncromune® @syncromune

3 weeks ago

#ICYMI Positive phase 1 data from the SYNC-T SV-102 trial was recently presented at #AACR24! Dive into the details and join the conversation surrounding these promising results. Click below to catch up on the latest buzz! bit.ly/43TPK1Z

0 0 2 112 0

Download Image

The ASCO Post @ASCOPost

3 weeks ago

Biologic Drug-Device Combination Immunotherapy in Metastatic Prostate Cancer ascopost.com/news/april-202… #pcsm #ProstateCancer #immunotherapy #oncology #AACR24 #AACR2024 @AACR

0 3 1 3K 1

AACR @AACR

3 weeks ago

SYNC-T, which combines cryolysis with multitarget immunotherapy, showed clinical activity against mCRPC, according to trial results presented by Charles Link, MD at #AACR24. bit.ly/4aMCFKa @mainlinehealth

1 2 3 2K 0

Download Image

Oncology Tube @oncologytube

3 weeks ago

Thank you Dr. Charles Link, PhD @syncromune for chatting with us on SYNC-T 85% ORR #ProstateCancer from #AACR24 @AACR Video Coming Soon!

1 3 5 1K 0

Download Image

Syncromune® @syncromune

4 weeks ago

Here at Syncromune we’re developing SYNC-T™, an in situ personalized cancer therapy that is designed to activate T cells and stimulate the immune system to treat metastatic solid tumors where other therapies have failed. Watch our animation to learn more: bit.ly/49e5pdB

0 0 1 59 0

Download Image

Syncromune® @syncromune

2 months ago

We’re pleased to announce that we have been selected for a late-breaking presentation at this year’s #AACR2024. The presentation will feature phase 1 data from studies of SV-102, developed from our SYNC-T Therapy platform. Learn more in our press release: syncromune.com/2024/03/06/syn…

0 0 2 118 0

Download Image

Syncromune® @syncromune

6 months ago

We had a great time at #SITC23, and enjoyed connecting with others in the cancer #immunotherapy space. Syncromune is committed to developing new therapies to help improve the lives of patients. Learn about our clinical trials: bit.ly/46EIbN7

0 0 2 121 0

Download Image

Syncromune® @syncromune

6 months ago

We’re pleased to welcome James Armitage, M.D., to Syncromune’s SAB as Advisory Board Chair. Dr. Armitage brings deep expertise and knowledge that will be invaluable to Syncromune’s clinical development programs. Learn more: bwnews.pr/49khoHK

0 0 1 70 0

Download Image

Syncromune® @syncromune

6 months ago

Let’s “Sync” up! Stop by our booth, #1032, next week at the @sitcancer Annual Meeting in San Diego! Learn about SYNC-T™, Syncromune’s investigational solid tumor treatment platform, using immunotherapy to target metastatic #solidtumors. #SITC2023

0 0 3 177 0

Download Image

Syncromune® @syncromune

2 years ago

Syncromune, Inc. Enters into an Exclusive Worldwide License Agreement with Eucure Biopharma Co., Ltd. dlvr.it/SbHS0Z

0 0 3 0 0

Download Image

Syncromune® @syncromune

2 years ago

Syncromune, Inc. to Present at the 2022 BIO CEO & Investor Conference businesswire.com/news/home/2022…

0 0 1 0 0

Cancer Research Institute @CancerResearch

3 years ago

June kicks off Cancer Immunotherapy Month™. Let's fuel the next scientific discoveries and breakthrough treatments through learning, engagement, and storytelling all month long. #CIM21 bit.ly/3uibxxF